The Journal of Nutritional Biochemistry
Volume 20, Issue 10 , Pages 806-815 , October 2009

Identification of a novel agonist of peroxisome proliferator-activated receptors α and γ that may contribute to the anti-diabetic activity of guggulipid in Lepob/Lepob mice

  • Claire L. Cornick

      Affiliations

    • Clore Laboratory for Life Sciences, University of Buckingham, MK18 1EG Buckingham, UK
    • ,
  • Barbara H. Strongitharm

      Affiliations

    • Biosciences Division, Unilever Research, Colworth Laboratory, Sharnbrook, MK44 1LQ Bedfordshire, UK
    • ,
  • Gary Sassano

      Affiliations

    • Biosciences Division, Unilever Research, Colworth Laboratory, Sharnbrook, MK44 1LQ Bedfordshire, UK
    • ,
  • Christopher Rawlins

      Affiliations

    • Biosciences Division, Unilever Research, Colworth Laboratory, Sharnbrook, MK44 1LQ Bedfordshire, UK
    • ,
  • Andrew E. Mayes

      Affiliations

    • Biosciences Division, Unilever Research, Colworth Laboratory, Sharnbrook, MK44 1LQ Bedfordshire, UK
    • ,
  • Alison N. Joseph

      Affiliations

    • Biosciences Division, Unilever Research, Colworth Laboratory, Sharnbrook, MK44 1LQ Bedfordshire, UK
    • ,
  • Jacqueline O'Dowd

      Affiliations

    • Clore Laboratory for Life Sciences, University of Buckingham, MK18 1EG Buckingham, UK
    • ,
  • Claire Stocker

      Affiliations

    • Clore Laboratory for Life Sciences, University of Buckingham, MK18 1EG Buckingham, UK
    • ,
  • Ed Wargent

      Affiliations

    • Clore Laboratory for Life Sciences, University of Buckingham, MK18 1EG Buckingham, UK
    • ,
  • Michael A. Cawthorne

      Affiliations

    • Clore Laboratory for Life Sciences, University of Buckingham, MK18 1EG Buckingham, UK
    • ,
  • A. Louise Brown

      Affiliations

    • Biosciences Division, Unilever Research, Colworth Laboratory, Sharnbrook, MK44 1LQ Bedfordshire, UK
    • ,
  • Jonathan R.S. Arch

      Affiliations

    • Clore Laboratory for Life Sciences, University of Buckingham, MK18 1EG Buckingham, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1280 820306; fax: +44 1280 820135.

Received 28 May 2008 ,Revised 24 July 2008 ,Accepted 29 July 2008.

References 

  1. Egan CD. Addressing use of herbal medicine in the primary care setting. J Am Acad Nurse Pract. 2002;14:166–171
  2. Raskin I, Ribnicky DM, Komarnytsky S, Ilic N, Poulev A, Borisjuk N, et al. Plants and human health in the twenty-first century. Trends Biotechnol. 2002;20:522–531
  3. Satyavati GV. Gum guggul (Commiphora mukul) — the success story of an ancient insight leading to a modern discovery. Indian J Med Res. 1988;87:327–335
  4. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290:765–772
  5. Urizar NL, Moore DD. Gugulipid: a natural cholesterol-lowering agent. Annu Rev Nutr. 2003;23:303–313
  6. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005;13:279–290
  7. Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev. 2007;25:375–390
  8. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science. 2002;296:1703–1706
  9. Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem. 2003;278:10214–10220
  10. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther. 2004;310:528–535
  11. Owsley E, Chiang JY. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun. 2003;304:191–195
  12. Ding X, Staudinger JL. The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. J Pharmacol Exp Ther. 2005;314:120–127
  13. Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol. 2005;67:948–954
  14. Subramaniam A, Stocker C, Sennitt MV, Wang S, Nolan AL, Brown L, et al. Guggul lipid reduces insulin resistance and body weight gain in C57Bl/6 lep/lep mice. Int J Obes. 2001;25(Suppl 2):S24
  15. Bosley JM, Brown AL, Roger JS. Food compositions for reducing insulin resistance. United States Patent. 2004;6737442:
  16. Kimura I, Yoshikawa M, Kobayashi S, Sugihara Y, Suzuki M, Oominami H, et al. New triterpenes, myrrhanol A and myrrhanone A, from guggul-gum resins, and their potent anti-inflammatory effect on adjuvant-induced air-pouch granuloma of mice. Bioorg Med Chem Lett. 2001;11:985–989
  17. Matsuda H, Morikawa T, Ando S, Oominami H, Murakami T, Kimura I, et al. Absolute stereostructures of polypodane-type triterpenes, myrrhanol A and myrrhanone A, from guggul-gum resin (the resin of Balsamodendron mukul). Chem Pharm Bull (Tokyo). 2004;52:1200–1203
  18. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32:5598–5604
  19. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem. 2002;277:11019–11025
  20. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, et al. Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol. 2001;21:7558–7568
  21. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem. 2002;277:31900–31908
  22. Kasturi R, Joshi VC. Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion of 3T3-L1 cells. J Biol Chem. 1982;257:12224–12230
  23. Fleming WW, Westfall DP, De la Lande IS, Jellett LB. Log-normal distribution of equieffective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther. 1972;181:339–345
  24. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, et al. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol. 2000;14:1425–1433
  25. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci. 2003;74:297–308
  26. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis. 2003;171:1–13
  27. Haluzik MM, Haluzik M. PPAR-alpha and insulin sensitivity. Physiol Res. 2006;55:115–122
  28. Owens DR. Thiazolidinediones — A pharmacological overview. Clin Drug Investig. 2002;22:485–505
  29. Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, et al. Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes Relat Metab Disord. 2005;29:864–871
  30. Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, et al. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes. 2006;55:2523–2533
  31. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell. 2001;8:737–747
  32. Misra P, Chakrabarti R, Vikramadithyan RK, Bolusu G, Juluri S, Hiriyan J, et al. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J Pharmacol Exp Ther. 2003;306:763–771
  33. Hu X, Feng Y, Shen Y, Zhao XF, Yu JH, Yang YS, et al. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. Acta Pharmacol Sin. 2006;27:1346–1352
  34. Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003;140:527–537
  35. Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, et al. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes. 2008;57:737–745
  36. Hummasti S, Laffitte BA, Watson MA, Galardi C, Chao LC, Ramamurthy L, et al. Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J Lipid Res. 2004;45:616–625
  37. Seo JB, Moon HM, Kim WS, Lee YS, Jeong HW, Yoo EJ, et al. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2004;24:3430–3444
  38. Juvet LK, Andresen SM, Schuster GU, Dalen KT, Tobin KA, Hollung K, et al. On the role of liver x receptors in lipid accumulation in adipocytes. Mol Endocrinol. 2003;17:172–182
  39. Krook A. Can the liver X receptor work its magic in skeletal muscle too?. Diabetologia. 2006;49:819–821
  40. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A. 2003;100:5419–5424
  41. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem. 2003;278:1131–1136
  42. Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab. 2005;289:E829–E838
  43. Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, et al. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology. 2006;147:5061–5068

☆ Funding: Claire Cornick was supported by the UK Biotechnology and Biological Sciences Research Council and Unilever Research.

☆☆ Unilever has applied for patents on commipheric acid but does not market commipheric acid or guggulipid.

PII: S0955-2863(08)00172-1

doi: 10.1016/j.jnutbio.2008.07.010

The Journal of Nutritional Biochemistry
Volume 20, Issue 10 , Pages 806-815 , October 2009

Article Tools

* Image Usage & Resolution